BTLA-TF tag mRNA-LNP

BTLA (B- and T-lymphocyte attenuator), also known as CD272, is a transmembrane glycoprotein belonging to the CD28 immunoglobulin superfamily (IgSF), encoded by the BTLA gene. BTLA is highly expressed in lymph nodes, thymus, and spleen, but not expressed or expressed at low levels in liver, kidney, heart, and brain. The BTLA ligand is herpes virus entry mediator (HVEM) belonging to the tumor necrosis factor receptor superfamily (TNFRSF). HVEM is present on T cells, B cells, NK cells, DCs, myeloid cells, and a variety of tumor cells. Ligation of BTLA by HVEM blocks activation, proliferation and cytokine production of B and T cells. BTLA shares structural and functional similarities with CTLA-4 and PD-1 and consists of extracellular, transmembrane and cytoplasmic domains. Similar to the checkpoint proteins CTLA-4 and PD-1, BTLA inhibits antigen receptor-stimulated activation in T and B cells upon HVEM binding by recruiting the phosphatases SHP1 and 2. BTLA/PD-1 co-expression was reported to be required for the dysfunction of infiltrating CD4+ T cells in human hepatocellular carcinoma. In mouse models, combined PD-1 and BTLA blockade restored T cell function and promoted tumor control more effectively than PD-1 blockade alone. This product is designed as a tool for the delivery and expression of human TF tagged BTLA mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of BTLA-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The BTLA-TF fusion protein is approximately 35 kD, consisting of BTLA (289 amino acids) and a C-terminal TF tag (15 amino acids). The GenPept accession number for BTLA is NP_861445.